Small molecule · Inhibitor of DNA topoisomerase I (TOP1) · developed by Nektar Therapeutics
Etirinotecan pegol is a pegylated, extended-release form of irinotecan, a prodrug that is converted to SN38. Its active metabolite stabilizes the topoisomerase I-DNA cleavable complex, causing DNA breaks that inhibit replication and trigger apoptosis. It is studied in solid tumors, including colorectal, ovarian, lung, and breast cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02915744 | Phase 3 | Metastasis | Completed | NKTR |
| NCT02312622 | Phase 2 | Stage IV Non-small Cell Lung Cancer (NSCLC) | Completed | NKTR |
| NCT01457118 | Phase 2 | Malignant Solid Tumor | Completed | NKTR |
| NCT00806156 | Phase 2 | Tumor | Completed | NKTR |
| NCT00598975 | Phase 2 | Tumor | Completed | NKTR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerColorectal CancerExtensive-stage Small Cell Lung Cancer (SCLC)Malignant Solid TumorMetastasisMetastatic Breast Cancer (mBC)Ovarian CancerRecurrent Non-small Cell Lung Cancer (NSCLC)Recurrent Small Cell Lung Cancer (SCLC)Stage IV Non-small Cell Lung Cancer (NSCLC)TumorTumors Metastatic to Brain
Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.
See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NKTR catalysts and pipeline →